Halozyme Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

HALO 9.62 +0.28 (3.00%)
price chart
Halozyme Therapeutics (HALO) Licenses ENHANZE Technology To Janssen
Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock gained 5.76% in pre-market trade today and has risen further during normal trading to $8.26, as at 12:26PM EST.
Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop ...  MarketWatch
Janssen Biotech licenses Halozyme's Enhanze technology  Seeking Alpha
Related articles »  
Worth Watching Stocks: Halozyme Therapeutics, Inc.(HALO), BioDelivery ...
Miami, Florida - Dec 27, 2014 - (Tech Sonian) - Halozyme Therapeutics, Inc.(NASDAQ:HALO), released that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency ...
Investor Watch: Halozyme Therapeutics, Inc. (NASDAQ:HALO), American ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) was initiated with buy rating coverage from analysts at MLV&Co which is being seen as a huge positive for the stock.
Benzinga's Top Initiations  Benzinga
Halozyme Therapeutics Earns Buy Rating from Analysts at MLV & Co (NASDAQ ...  WKRB News
Related articles »  
Why Halozyme Therapeutics Inc. Shares Surged
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Why Halozyme Therapeutics Was Upgraded To 'Buy' This Morning  TheStreet.com
Related articles »  
Notable Upgrades: Virgin America (VA), Achillion Pharma (ACHN), Chesapeake ...
MLV & Co analysts are out with a report this morning initiating coverage of Halozyme Therapeutics, Inc. (HALO) with a 'Buy' rating and $12 price target.
Why Halozyme Therapeutics Inc. Shares Shot Higher
What: Shares of Halozyme Therapeutics (NASDAQ: HALO ) , a biopharmaceutical company that develops human enzymes that alter human tissues and make for more effective drug delivery, jumped as much as 25% after reporting its first-quarter results and ...
Halozyme Rallies Despite Poor First-Quarter Performance  Bidness Etc
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2014 Results ...  Seeking Alpha
Related articles »  
Why Halozyme Therapeutics Inc. Shares Soared
What: Shares of Halozyme Therapeutics (NASDAQ: HALO ) , a biopharmaceutical company focused on developing human enzymes which help facilitate the drug delivery process, surged as much as 21% after announcing that it planned to resume patient ...
Halozyme Gets New Hope for Shareholders, and for Pancreatic Cancer Patients  24/7 Wall St.
Halozyme To Resume PEGPH20 Clinical Program In Pancreatic Cancer  MarketWatch
Related articles »  
Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 1:00 p.m.
Why Halozyme Therapeutics Inc. Shares Plummeted
What: Shares of Halozyme Therapeutics (NASDAQ: HALO ) plunged 26% on Friday after the company announced that it is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating the drug in patients ...
Pancreatic Cancer Trial Enrollment Halt Damages Halozyme  24/7 Wall St.
Halozyme Down With Other Biotech Stocks  Bidness Etc
Related articles »  
Halozyme Therapeutics Plummets On Q3 Losses
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported financial results Monday for the third quarter ended September 30, 2014.
Halozyme Therapeutics Plunge 12% As Q3 Results Miss Estimates  Nasdaq
Halozyme Reports Third Quarter 2014 Financial Results  MarketWatch
Related articles »